Evolocumab prior authorization at UPMC Health Plan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
UPMC Health Plan reviews Evolocumab prior authorizations against its medical policy . UPMC Health Plan-specific context: Integrated payer-provider arm of UPMC (~4M members). Western PA dominant. The Highmark-UPMC consent decree (expired June 2019) governed cross-network access historically; subsequent commercial agreements maintain some access. PA Insurance Department oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- UPMC Health Plan's medical policy URL referenced in the cover letter
UPMC Health Plan's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Highmark-vs-UPMC network access disputes (historical PA consent decree)
- Specialty drug PA
- Behavioral health prior auth
- Out-of-network reductions
If the PA is denied
UPMC Health Plan gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.upmchealthplan.com/providers) with the same packet plus a peer-reviewed citation supporting Evolocumabfor the patient's indication.
Contact UPMC Health Plan
- Provider portal: https://www.upmchealthplan.com/providers
Frequently asked questions
What documentation does UPMC Health Plan need for Evolocumab prior auth?
UPMC Health Plan's typical PA packet for Evolocumab: (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at UPMC Health Plan?
Standard Evolocumab PA decisions at UPMC Health Plan: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does UPMC Health Plan most often reject Evolocumab for?
Across UPMC Health Plan's book the common rejection patterns include: Highmark-vs-UPMC network access disputes (historical PA consent decree); Specialty drug PA; Behavioral health prior auth. For Evolocumab specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with UPMC Health Plan on Evolocumab?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the Evolocumab PA packet
Open ApprovalHelp — generate a Evolocumab prior-auth packet tailored to UPMC Health Plan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com